apatinib treatment for advanced esophagus cancer

Conditions: Advanced Esophagus Cancer

Summary: subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.


Eligibility criteria:
inclusion criteria: * 1. age: 18 to 75 years old, men and women; * 2. after histopathological and immunohistochemical examination diagnosis of esophageal squamous cell carcinomas. at least one measurable lesion after the treatment (the length to diameter of ct scan≥10 mm , accord with the requirement of rescist 1.1);the lesions of whom had not received radiotherapy. * 3. advanced esophageal squamous cell carcinoma without molecular targeted drug therapy; * 4. ecog ps:0-1; * 5. life expectancy≥12 weeks; * 6. patients who have disease progressed or relapsed after standard chemotherapy, or who have been unable to tolerate chemotherapy; * 7. the main organs function properly, that is, meet the following criteria: 1. blood routine examination: hb≥90 g / l; (without blood transfusion during 14 days) anc≥1.5×109 /l; plt≥80×109 / l; 2. biochemical examination: alb≥30g / l; (without infusion of albumin during 14 days) alt and ast\<2uln; tbil≤1.5uln; plasma cr≤1.5uln; * 8. the results of the serum pregnancy test of women in childbearing age must be negative in the 7 days prior to treatment; all patients (both male and female) should take adequate barrier contraception within the entire treatment and 4 weeks after treatment. * 9. subject should volunteer to join the study, sign the informed consent, have good compliance and cooperate with the follow-up; * 10. investigator believe that subject who can benefit. exclusion criteria: * 1. in the past or at the same time with suffered from other malignancies; * 2. pregnant or lactating women; * 3. patients with high blood pressure and can't get a good control after antihypertensive drug therapy (systolic blood pressure\>150mmhg, diastolic blood pressure\>100mmhg); patients with grade ⅱ or more myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including qtc interval≥450ms) and ⅲ\~ⅳ grade cardiac insufficiency according to nyha; cardiac color doppler ultrasonography: lvef \<50%; * 4. unable to swallow, chronic diarrhea and intestinal obstruction, significantly affect the drug taking and absorption; * 5. with a clear risk of gastrointestinal bleeding (such as locally active ulcer lesions, fecal occult blood above + +), history of gastrointestinal bleeding within 6 months, and unhealed wounds; * 6. central nervous system metastasis has occurred; * 7. with abnormal coagulation function (pt\>16s, aptt\>43s, tt\>21s, fbg\<2g/l), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; * 8. with mental illness, or mental history of drug abuse; * 9. with anastomotic recurrence; * 10. patients who have participated in other drug clinical trials in 4 weeks; * 11. patients who have concomitant diseases that are seriously compromise the patient's safety or affect the patient to complete the study according to the researcher's judgment; * 12. patients those researchers believe not suitable for the inclusion.